Biovail loses effort to stop generic Wellbutrin

Biovail has lost a last-ditch attempt to prevent copycat versions of its popular antidepressant Wellbutrin from hitting the market. A federal judge has ruled against a move to gain a temporary restraining order and an injunction against the FDA to prevent it from approving a generic. The ruling clears the path for Anchen to start selling a competing generic.

- here's the AP report on the ruling